The clinical trial management system (CTMS) market is projected to grow from $2.54 billion in 2026 to $4.2 billion by 2030, with a CAGR of 13.4%. Growth is driven by increasing global clinical trials, adoption of decentralized and AI-driven trial models, and investments in digital infrastructure. Key trends include cloud-based platforms, real-time monitoring, and regulatory compliance automation. North America leads the market currently, while Asia Pacific is expected to see the fastest growth. Major players include Oracle, Veeva Systems, and BioClinica. This growth reflects the rising complexity and demand for efficient clinical trial oversight and management.
Oracle shares recently dropped sharply amid market concerns despite $67 billion in AI deals and $70 billion planned spending. Historically, Oracle stock falls an average of 18% during market crises, worse than the S&P 500, with declines up to 40% in ...
Tradr ETFs has introduced two new leveraged ETFs that provide twice the inverse daily performance (-200%) of Applied Optoelectronics and Oracle stocks. These funds, listed on Cboe, offer traders tools to profit from or hedge against declines in these...
Oracle is transforming from a traditional software company into a hyperscaler focused on AI-driven cloud infrastructure. The company faces risks from high debt and customer concentration, notably with OpenAI, but its accelerating cloud revenue and la...
Oracle introduced a new AI Studio Skill within Oracle AI Agent Studio for Fusion Applications, enabling customers and partners to build AI-driven Fusion Agentic Applications natively inside Oracle Fusion Cloud. These applications use specialized AI a...
Bealls Inc., a 111-year-old US retailer, improved its clearance pricing strategy by adopting Oracle Retail Lifecycle Pricing Optimization (LPO). This AI-driven solution replaces fixed markdown schedules with dynamic pricing based on real-time demand,...
